In this article, we will list the 5 Small Cap Stocks with the Highest Upside Potential. Please visit 7 Small Cap Stocks with the Highest Upside Potential to see the extended list and the methodology behind it.

5. Phoenix Education Partners Inc. (NYSE:PXED)

Average Upside Potential: 69.05%

Phoenix Education Partners Inc. (NYSE:PXED) is one of the small cap stocks with the highest upside potential. On April 7, Phoenix Education Partners reported financial results for FQ2 2026, recording net revenue of $222.5 million and a net income of $10.8 million, or $0.28 diluted EPS. While net revenue remained relatively stable compared to the previous year, the company saw a rise in Average Total Degreed Enrollment to 82,600 students. The decrease in net income from $16.1 million in the prior year’s quarter was attributed to share-based compensation costs linked to the company’s IPO.

The CEO highlighted the institution’s success in student satisfaction, noting that the University of Phoenix exceeded national benchmarks across 26 attributes in the Priorities Survey for Online Learners. The company also issued over one million digital badges to students and alumni to verify career-relevant skills. Strategically, the Board of Directors approved a new $50 million share repurchase program and declared a common stock cash dividend of $0.21 per share, payable on May 22.

As of February 28, the company maintained a strong liquidity position with $252.1 million in cash, equivalents, and marketable securities, supported by $80 million in cash generated from operating activities during H1. For FY26, Phoenix Education Partners Inc. (NYSE:PXED) projects net revenue to fall between $1,025 and $1,035 million, with Adjusted EBITDA to range from $244 to $249 million.

Phoenix Education Partners Inc. (NYSE:PXED) is a pioneer in online higher education for working adults. The company provides talent solutions for employers, using AI-powered tools and talent-sourcing platforms to align student skill profiles with internal development pathways and job opportunities.

4. CRA International Inc. (NASDAQ:CRAI)

Average Upside Potential: 71.23%

CRA International Inc. (NASDAQ:CRAI) is one of the small cap stocks with the highest upside potential. On April 16, CRA International announced the return of Hitesh Makhija as Vice President within its Antitrust & Competition Economics Practice. Makhija, who previously spent a decade at the firm between 2012 and 2022, rejoins CRA after serving as a VP for another major international economics consultancy. He specializes in industrial organization and antitrust economics, bringing extensive experience in complex economic and financial analyses for high-stakes litigation and regulatory matters.

Throughout his career, Makhija has advised numerous Fortune 100 companies on the antitrust risks associated with strategic decision-making and mergers. His expertise spans a diverse range of sectors, including semiconductors, software, retail, oil and gas, and the airline industry. He has a proven track record of submitting evidence to major regulatory bodies, including the US Federal Trade Commission, the US Department of Justice, the European Commission, and the Canadian Competition Bureau.

CRA International Inc. (NASDAQ:CRAI) leadership emphasized that Makhija’s ability to lead teams through all phases of the litigation process strengthens the firm’s global capabilities. His academic background includes a Bachelor of Engineering in Computer Engineering from the University of Mumbai, followed by a Master of Arts degree in Economics from both New York University and the University of Minnesota.

CRA International Inc. (NASDAQ:CRAI), also known as Charles River Associates, is a global consulting firm specializing in economic, financial, and management services. The firm advises corporations and attorneys on litigation, regulatory proceedings, and business strategy.

3. Compass Pathways (NASDAQ:CMPS)

Average Upside Potential: 102.77%

Compass Pathways (NASDAQ:CMPS) is one of the small cap stocks with the highest upside potential. On April 24, Compass Pathways announced that the US FDA granted a rolling review for its NDA and selected COMP360 for the Commissioner’s National Priority Voucher/CNPV program. COMP360 is a proprietary synthetic psilocybin formulation designed for patients with treatment-resistant depression/TRD.

The CNPV designation provides the company with enhanced regulatory communication and a significantly shortened review timeline of one to two months once the application is filed, though the drug must still meet all standard FDA requirements for safety and efficacy. The decision is supported by positive data from two large Phase 3 clinical trials involving over 1,000 participants. These trials demonstrated that COMP360 could produce clinically meaningful effects as quickly as one day after administration, with results lasting at least six months for many patients.

The safety profile indicated that most adverse events were mild to moderate and typically resolved within 24 hours. The CEO emphasized that this regulatory progress validates the urgent need for innovation in the mental health field, particularly for the estimated 4 million people in the US living with TRD. As the most advanced company in the field of classic psychedelics, Compass Pathways (NASDAQ:CMPS) is currently preparing for the commercial launch of COMP360.

Compass Pathways (NASDAQ:CMPS) is a biotech company focused on developing psychedelic treatments for mental health issues. Its flagship drug candidate COMP360 is being developed as a solution for treatment-resistant depression as well as post-traumatic stress disorder.

2. Sana Biotechnology (NASDAQ:SANA)

Average Upside Potential: 107.10%

Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the development of SC451, an investigational cell replacement therapy for type 1 diabetes. SC451 uses Sana Biotech’s proprietary hypoimmune technology to engineer pancreatic islet cells that can survive and function without the need for traditional immunosuppression or daily insulin injections.

As part of this partnership, Mayo Clinic has made an equity investment in Sana Biotech, reflecting a shared goal of creating potentially curative therapies that can be standardized and scaled for global use. The collaboration focuses on using Mayo Clinic’s multidisciplinary expertise to refine the clinical and operational protocols necessary for delivering SC451. Efforts will include optimizing product handling, refining surgical procedural techniques, and improving post-treatment care to ensure the therapy can be adopted across various clinical environments.

Additionally, Mayo Clinic will provide leadership in clinical trial design and biomarker identification to enhance patient selection and long-term monitoring as the therapy moves toward human trials. Sana Biotechnology (NASDAQ:SANA) aims to initiate a Phase 1 clinical study for SC451 as early as this year, bolstered by recent data showing that hypoimmune-modified islets survived and produced insulin in a patient for over 14 months without immunosuppression.

Sana Biotechnology (NASDAQ:SANA) is a biotech company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders.

1. Annexon Inc. (NASDAQ:ANNX)

Average Upside Potential: 109.38%

Annexon Inc. (NASDAQ:ANNX)  is one of the small cap stocks with the highest upside potential. On March 30, the company reported its 2025 year-end financial results, highlighting a period of significant clinical and regulatory progress for its neuroinflammatory disease platform. The company ended the year with a strong balance sheet featuring $238.3 million in cash and short-term investments, a figure supported by an $86.3 million public offering in late 2025.

This capital is expected to provide a financial runway into H2 2027, supporting the advancement of two late-stage registrational programs and an emerging oral inhibitor. The company’s lead candidate, vonaprument, is currently being evaluated in the ARCHER II Phase 3 trial for geographic atrophy/GA, with topline data anticipated in Q4 2026. Unlike existing treatments that target downstream proteins, vonaprument utilizes an upstream C1q blockade designed to protect photoreceptor neurons and preserve vision.

The program has notably received PRIME designation from the European Medicines Agency, establishing a clear global regulatory path for what could be the first vision-preserving therapy for the millions affected by GA worldwide. Simultaneously, Annexon Inc. (NASDAQ:ANNX) is advancing tanruprubart for the treatment of Guillain-Barré Syndrome/GBS.

Annexon Inc. (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company advancing a platform of targeted immunotherapies for neuroinflammatory and autoimmune diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.